We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 23, 2009
Last Update Posted: March 10, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
VSL Pharmaceuticals
Information provided by (Responsible Party):
Julia Bracken, Children's Mercy Hospital Kansas City
The purpose of this study is to determine the effect of a probiotic formulation, VSL#3, on intestinal permeability in pediatric patients with Crohn's disease.

Condition Intervention Phase
Crohn's Disease Dietary Supplement: VSL#3 Dietary Supplement: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission

Resource links provided by NLM:

Further study details as provided by Julia Bracken, Children's Mercy Hospital Kansas City:

Primary Outcome Measures:
  • Intestinal Permeability - measured by Sugar Absorption Test [ Time Frame: 3 months ]

Enrollment: 12
Study Start Date: July 2009
Study Completion Date: July 2013
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: VSL#3 Dietary Supplement: VSL#3
1 packet BID
Placebo Comparator: Placebo Dietary Supplement: Placebo
1 inactive packet BID

Detailed Description:
Children with Crohn's disease have altered intestinal permeability. A pilot study in children showed that probiotics may decrease intestinal permeability. In this double blind, randomized controlled trial, we will observe the effect of VSL#3 on small bowel permeability using a double sugar absorption test. PCDAI was monitored, but not analyzed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   11 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Current diagnosis of small bowel or colonic Crohn's disease as defined by histological and endoscopic criteria.
  • Males or females ages 11-17 years.
  • Crohn's disease in remission as defined by a Pediatric Crohn's Disease Activity Index (PCDAI) < 10
  • Patients on maintenance doses of aminosalicylates, 6-MP and/or Azathioprine for at least 2 months.
  • Procurement of written informed consent signed by the subject's legal guardian and study investigator(s) and patient assent.

Exclusion Criteria:

  • Patients with documented intestinal stricture.
  • Patients with signs of symptoms of systemic or intestinal infection.
  • Antibiotic use the previous 1 month.
  • Probiotic use in the previous 2 months (excluding yogurt).
  • Use of the following medications; Methotrexate, Cyclosporine, Tacrolimus and Infliximab.
  • Patients with diagnosis of other co-morbid diseases such as heart disease, renal disease, immunodeficiency, diabetes, or thyroid disease.
  • Patients with indwelling catheters.
  • Patients with short bowel syndrome
  • Positive urine pregnancy test for female subjects
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944736

United States, Missouri
The Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
Sponsors and Collaborators
Children's Mercy Hospital Kansas City
VSL Pharmaceuticals
Principal Investigator: Julia M Bracken, MD Children's Mercy Hospital
  More Information

Responsible Party: Julia Bracken, Assistant Professor of Medicine, Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier: NCT00944736     History of Changes
Other Study ID Numbers: 09 06-115
First Submitted: July 22, 2009
First Posted: July 23, 2009
Last Update Posted: March 10, 2014
Last Verified: March 2014

Keywords provided by Julia Bracken, Children's Mercy Hospital Kansas City:
Crohn's Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases